Australia's Genetic Signatures climbs on potential merger with Microba

Genetic Signatures

26/08/2026 06:40

** Shares of Australia's Genetic Signatures GSS.AX rise as much as 6.9% to A$0.0855, hitting their highest level since May 4
** Medical equipment and tech co says it is in discussions with gut microbiome diagnostics firm Microba Life Sciences MAP.AX regarding a potential merger 
** Co says Microba’s current gastrointestinal (GI) diagnostics portfolio is complementary to GSS’s existing GI offering 
** Adds, on a pro forma basis, the merged group would have FY2026 revenue of approximately A$29 million ($20.81 million)and combined cash and term deposits of approximately A$30 million as at 30 June 2026
** About 543,772 shares change hands, about 1.9x the 30-day average
** YTD, stock down 66.8%, including session's moves 


($1 = 1.3933 Australian dollars)

 (Reporting by Subhalakshmi Dey in Bengaluru)
 ((Subhalakshmi.Dey@thomsonreuters.com;))